Adalimumab Biosimilar Transition Studies Reported at ECCO’21 Congress – The Center for Biosimilars

Presentations at the European Crohn’s and Colitis Organization annual meeting supported the transition to adalimumab biosimilars and provided patient acceptance data.

CONTEXT:  Among the poster presentations described in this article is details of interim analysis data from the PROPER study at the Congress of the European Crohn’s and Colitis Organisation (ECCO ’21) revealed that despite limited knowledge and concerns about transitioning, patients generally accept the principals of biosimilars and can be reassured about receiving them.  The PROPER study is a pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn’s disease.  READ TIME:  3 mins 1. “Acceptance of switch, patient satisfaction and adverse events after switch from adalimumab originator to biosimilar SB5 in patients with inflammatory bowel disease in a real-life setting.”  2. “In a study of patients with inflammatory bowel disease who switched to an adalimumab biosimilar (SB5, Hadlima) after achieving stability on Humira, investigators concluded adalimumab trough levels were comparable at up to 1-year post-switch.”  3. “Patients with inflammatory bowel disease (N = 110) were gauged according to their acceptance of a switch to an adalimumab biosimilar (SB5, Hadlima) after achieving disease stability on the originator product (Humira).”  4. “An interim analysis of the PROPER study of patients with Crohn disease who transitioned to an adalimumab biosimilar (SB5, Hadlima) following treatment with the reference product (Humira) demonstrated that most patients had no meaningful difference in disease activity or Hadlima dosing regimen by week 48 following transition to the biosimilar.”  5. “Based on an ongoing crossover study enrolling patients with Crohn disease (N = 112) transitioning between Humira and the adalimumab biosimilar Imraldi, investigators concluded that despite limited knowledge and concerns about transitioning, patients generally accept the principals of biosimilars and can be reassured about receiving them.”  Source URL: https://www.centerforbiosimilars.com/view/adalimumab-biosimilar-transition-studies-reported-at-ecco-21-congress